Article Contents ::
- 1 Details About Generic Salt :: Toremife
- 2 Main Medicine Class::
- 3 (TORE-EM-ih-feen) Fareston Oral tablets 60 mg Class: Antiestrogen hormone Indications Metastatic breast cancer in postmenopausal women. Contraindications Standard considerations. Route/Dosage Breast Cancer ADULTS: PO 60 mg once daily with or without food. Interactions Anticonvulsants May increase toremifene clearance by 2-fold. CYP3A4 Toremifene may be altered by drugs that inhibit (eg, ketoconazole, itraconazole, macrolides) or induce (eg, phenobarbital, phenytoin, carbamazepine) this enzyme. Thiazide diuretics May cause hypercalcemia with agents that reduce renal excretion of calcium. Warfarin May increase the hypoprothrombinemic effect of warfarin. Lab Test Interferences None well documented. Adverse Reactions CARDIOVASCULAR: Edema; pulmonary embolism; thrombophlebitis; thrombosis; cerebrovascular accident; transient ischemic attack; cardiac failure; MI. CNS: Dizziness. ENDOCRINE: Hot flashes; sweating. GI: Nausea and vomiting; elevated LFTs. GU: Vaginal discharge; vaginal bleeding; endometrial thickening. METABOLIC: Hypercalcemia. MUSCULOSKELETAL: Bone and tumor pain at initiation of therapy; soft tissue lesions can temporarily increase in size. SPECIALSENSES: Cataracts; dry eyes; abnormal visual fields; corneal keratopathy; glaucoma; abnormal vision; diplopia. Precautions Pregnancy: Category D. Lactation: Undetermined. Children: Safety and efficacy not established. Hypercalcemia and tumor flare: Drugs that decrease renal calcium excretion (eg, thiazide diuretics) may increase the risk of hypercalcemia in patients receiving toremifene. Hepatic dysfunction: Metabolized in the liver; dose reduction may be necessary in patients with liver disease. Thromboembolic disease: Caution in patients with thromboembolic diseases. Preexisting endometrial hyperplasia: Avoid long-term use. PATIENT CARE CONSIDERATIONS Administration/Storage Store at room temperature. Protect from heat and light. Administer PO without regards to food. Assessment/Interventions Tumor flare and hypercalcemia may occur during the first few weeks of treatment. Monitor serum calcium concentrations periodically. Monitor CBC and LFTs periodically during therapy. Monitor leukocyte and platelet counts. OVERDOSAGE: SIGNS & SYMPTOMS Vertigo, headache, dizziness, nausea, vomiting, reversible hallucinations, ataxia Patient/Family Education Instruct patient to contact the health care provider if vaginal bleeding occurs. Inform patient with bone metastases of typical signs/symptoms of hypercalcemia. Contact the health care provider if such signs or symptoms occur. Medicscientist Drug Facts
- 4 Drugs Class ::
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
Details About Generic Salt :: Toremife
Main Medicine Class::
(TORE-EM-ih-feen)
Fareston
Oral tablets
60 mg
Class: Antiestrogen hormone
Indications Metastatic breast cancer in postmenopausal women.
Contraindications Standard considerations.
Route/Dosage
Breast Cancer
ADULTS: PO 60 mg once daily with or without food.
Interactions
Anticonvulsants
May increase toremifene clearance by 2-fold.
CYP3A4
Toremifene may be altered by drugs that inhibit (eg, ketoconazole, itraconazole, macrolides) or induce (eg, phenobarbital, phenytoin, carbamazepine) this enzyme.
Thiazide diuretics
May cause hypercalcemia with agents that reduce renal excretion of calcium.
Warfarin
May increase the hypoprothrombinemic effect of warfarin.
Lab Test Interferences None well documented.
Adverse Reactions
CARDIOVASCULAR: Edema; pulmonary embolism; thrombophlebitis; thrombosis; cerebrovascular accident; transient ischemic attack; cardiac failure; MI. CNS: Dizziness. ENDOCRINE: Hot flashes; sweating. GI: Nausea and vomiting; elevated LFTs. GU: Vaginal discharge; vaginal bleeding; endometrial thickening. METABOLIC: Hypercalcemia. MUSCULOSKELETAL: Bone and tumor pain at initiation of therapy; soft tissue lesions can temporarily increase in size. SPECIALSENSES: Cataracts; dry eyes; abnormal visual fields; corneal keratopathy; glaucoma; abnormal vision; diplopia.
Precautions
Pregnancy: Category D. Lactation: Undetermined. Children: Safety and efficacy not established. Hypercalcemia and tumor flare: Drugs that decrease renal calcium excretion (eg, thiazide diuretics) may increase the risk of hypercalcemia in patients receiving toremifene. Hepatic dysfunction: Metabolized in the liver; dose reduction may be necessary in patients with liver disease. Thromboembolic disease: Caution in patients with thromboembolic diseases. Preexisting endometrial hyperplasia: Avoid long-term use.
PATIENT CARE CONSIDERATIONS
Administration/Storage
- Store at room temperature. Protect from heat and light.
- Administer PO without regards to food.
Assessment/Interventions
- Tumor flare and hypercalcemia may occur during the first few weeks of treatment. Monitor serum calcium concentrations periodically.
- Monitor CBC and LFTs periodically during therapy.
- Monitor leukocyte and platelet counts.
OVERDOSAGE: SIGNS & SYMPTOMS
Vertigo, headache, dizziness, nausea, vomiting, reversible hallucinations, ataxia
Patient/Family Education
- Instruct patient to contact the health care provider if vaginal bleeding occurs.
- Inform patient with bone metastases of typical signs/symptoms of hypercalcemia. Contact the health care provider if such signs or symptoms occur.
Medicscientist Drug Facts
PATIENT CARE CONSIDERATIONS
OVERDOSAGE: SIGNS & SYMPTOMS | |
Vertigo, headache, dizziness, nausea, vomiting, reversible hallucinations, ataxia |
Drugs Class ::
(TORE-EM-ih-feen) |
Fareston |
Oral tablets |
60 mg |
Class: Antiestrogen hormone |
Indications for Drugs ::
Indications Metastatic breast cancer in postmenopausal women.
Drug Dose ::
Route/Dosage
Breast Cancer
ADULTS: PO 60 mg once daily with or without food.
Contraindication ::
Contraindications Standard considerations.
Drug Precautions ::
Precautions
Pregnancy: Category D. Lactation: Undetermined. Children: Safety and efficacy not established. Hypercalcemia and tumor flare: Drugs that decrease renal calcium excretion (eg, thiazide diuretics) may increase the risk of hypercalcemia in patients receiving toremifene. Hepatic dysfunction: Metabolized in the liver; dose reduction may be necessary in patients with liver disease. Thromboembolic disease: Caution in patients with thromboembolic diseases. Preexisting endometrial hyperplasia: Avoid long-term use.
PATIENT CARE CONSIDERATIONS |
|
Drug Side Effects ::
Adverse Reactions
CARDIOVASCULAR: Edema; pulmonary embolism; thrombophlebitis; thrombosis; cerebrovascular accident; transient ischemic attack; cardiac failure; MI. CNS: Dizziness. ENDOCRINE: Hot flashes; sweating. GI: Nausea and vomiting; elevated LFTs. GU: Vaginal discharge; vaginal bleeding; endometrial thickening. METABOLIC: Hypercalcemia. MUSCULOSKELETAL: Bone and tumor pain at initiation of therapy; soft tissue lesions can temporarily increase in size. SPECIALSENSES: Cataracts; dry eyes; abnormal visual fields; corneal keratopathy; glaucoma; abnormal vision; diplopia.
Drug Mode of Action ::
(TORE-EM-ih-feen) |
Fareston |
Oral tablets |
60 mg |
Class: Antiestrogen hormone |
Drug Interactions ::
Interactions
Anticonvulsants
May increase toremifene clearance by 2-fold.
CYP3A4
Toremifene may be altered by drugs that inhibit (eg, ketoconazole, itraconazole, macrolides) or induce (eg, phenobarbital, phenytoin, carbamazepine) this enzyme.
Thiazide diuretics
May cause hypercalcemia with agents that reduce renal excretion of calcium.
Warfarin
May increase the hypoprothrombinemic effect of warfarin.
Drug Assesment ::
Assessment/Interventions
- Tumor flare and hypercalcemia may occur during the first few weeks of treatment. Monitor serum calcium concentrations periodically.
- Monitor CBC and LFTs periodically during therapy.
- Monitor leukocyte and platelet counts.
|
Drug Storage/Management ::
Administration/Storage
- Store at room temperature. Protect from heat and light.
- Administer PO without regards to food.
Drug Notes ::
Patient/Family Education
- Instruct patient to contact the health care provider if vaginal bleeding occurs.
- Inform patient with bone metastases of typical signs/symptoms of hypercalcemia. Contact the health care provider if such signs or symptoms occur.
Medicscientist Drug Facts